Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient population

Métastases cérébrales dans les tumeurs germinales (stratégie thérapeutique)

LYON1-BU Santé (693882101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Etude rétrospective de pratique du curage ganglionnaire lombo-aortique après chimiothérapie des tumeurs germinales non séminomateuses testiculaires et rétropéritonéales primitives

LYON1-BU Santé (693882101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Problématiques de la prise en charge des tumeurs germinales métastatiques

Les tumeurs germinales sont les plus fréquentes de l'homme jeune. Les traitements sont standardisés depuis une vingtaine d'année. Dans les formes métastatiques, ils reposent sur une chimiothérapie à base de cisplatine et l'exérèse de toutes les masses résiduelles. Notre travail clinique dans la prise en charge des patients atteints d'une tumeur germinale au Centre Léon Beréarard (CLB) nous a amené à nous poser plusiers questions. Nous avons analysé de façon rétrosptective le rôle de la chimiothérapie intensive, l'efficacité des traitements après échec de la chimiothérapie intensive, la chirurgie des masses résiduelles des séminomes après chimiothérapie et les modalités de surveillance après traitement [...]LYON1-BU.Sciences (692662101) / SudocSudocFranceF

Chemotherapy in advanced bladder cancer: current status and future

Abstract Bladder cancer occurs in the majority of cases in males. It represents the seventh most common cancer and the ninth most common cause of cancer deaths for men. Transitional cell carcinoma is the most predominant histological type. Bladder cancer is highly chemosensitive. In metastatic setting, chemotherapy based on cisplatin should be considered as standard treatment of choice for patients with good performance status (0-1) and good renal function-glomerular filtration rate (GFR) > 60 mL/min. The standard treatment is based on cisplatin chemotherapy regimens type MVAC, HD-MVAC, gemcitabine plus cisplatin (GC) or dose dense GC. In unfit patients, carboplatin based regimes; gemcitabine plus carboplatin or methotrexate plus carboplatin plus vinblastine (MCAVI) are reasonable options. The role of targeted therapies when used alone, or in combination with chemotherapy, or in maintenance, was evaluated; targeting angiogenesis seem to be very promising. The purpose of this literature review is to highlight the role of chemotherapy in the management of advanced transitional cell carcinoma of the bladder.</p

La TEP au 68Ga-PSMA et autres traceurs TEP

International audienc

À propos d’un cas de cancer du pénis avec atteinte ganglionnaire iliaque pris en charge par radiothérapie et gemcitabine concomitante

International audiencePenile cancer is a rare entity with only 2000 new cases a year in the United States. Even though early stage penile cancer has an excellent prognosis, patients with positive pelvic lymph nodes have an overall 5-year survival rate under 10%. There is no consensus for the management of pelvic node-positive patients, although most guidelines are in favour of pelvic lymph node dissection for patients with two or more positive nodes, followed by adjuvant chemotherapy. We describe here the case of a patient with numerous metastatic lymph nodes at diagnosis, treated with chemoradiation (66Gy with concurrent gemcitabine) after failure of first-line chemotherapy and still alive and disease-free 7 years after diagnosis